These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 33944659)
1. Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. Cuesta-Mateos C; Juárez-Sánchez R; Mateu-Albero T; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C MAbs; 2021; 13(1):1917484. PubMed ID: 33944659 [TBL] [Abstract][Full Text] [Related]
2. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159 [TBL] [Abstract][Full Text] [Related]
3. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target. Cuesta-Mateos C; Brown JR; Terrón F; Muñoz-Calleja C Front Immunol; 2021; 12():662866. PubMed ID: 33841445 [TBL] [Abstract][Full Text] [Related]
4. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax. Mateu-Albero T; Marcos-Jimenez A; Delgado-Wicke P; Terrón F; Loscertales J; López-Matencio JMS; Muñoz-Calleja C; Cuesta-Mateos C Hematol Oncol; 2023 Dec; 41(5):869-876. PubMed ID: 37545392 [TBL] [Abstract][Full Text] [Related]
6. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224 [TBL] [Abstract][Full Text] [Related]
7. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605 [TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Redondo-Muñoz J; José Terol M; García-Marco JA; García-Pardo A Blood; 2008 Jan; 111(1):383-6. PubMed ID: 17890452 [TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cuesta-Mateos C; Loscertales J; Kreutzman A; Colom-Fernández B; Portero-Sáinz I; Pérez-Villar JJ; Terrón F; Muñoz-Calleja C Cancer Immunol Immunother; 2015 Jun; 64(6):665-76. PubMed ID: 25724841 [TBL] [Abstract][Full Text] [Related]
10. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Till KJ; Lin K; Zuzel M; Cawley JC Blood; 2002 Apr; 99(8):2977-84. PubMed ID: 11929789 [TBL] [Abstract][Full Text] [Related]
11. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443 [TBL] [Abstract][Full Text] [Related]
12. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. Chunsong H; Yuling H; Li W; Jie X; Gang Z; Qiuping Z; Qingping G; Kejian Z; Li Q; Chang AE; Youxin J; Jinquan T J Immunol; 2006 Nov; 177(10):6713-22. PubMed ID: 17082584 [TBL] [Abstract][Full Text] [Related]
13. Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia. Catusse J; Leick M; Groch M; Clark DJ; Buchner MV; Zirlik K; Burger M Mol Cancer; 2010 Nov; 9():297. PubMed ID: 21092185 [TBL] [Abstract][Full Text] [Related]